Increased expression of NRP1 and NRP2 was mainly associated with poor prognosis: NRP1 associated with poor OS for ACC, cervical & endocervical cancer (CESC), LGG, MESO, and STAD, while NRP2 associated with poor prognosis for bladder urothelial carcinoma (BLCA), KIRP, MESO, PAAD, and STAD, respectively. Here, NRP1 is linked to endocervical carcinoma.